Repository logo
 
Publication

Challenging Clinical Cases – A Walk Through Supplemental Therapy with Intravitreal Ranibizumab Therapy Following Treatment of Diabetic Macular Edema with the 0.19 mg Fluocinolone Acetonide Implant (ILUVIEN®)

2020-09-15Journal article Open access
Simple item page
dc.contributor.authorPessoa, Bernardete
dc.contributor.authorBeirão, João
dc.contributor.authorMeireles, Angelina
dc.contributor.authorMenéres, Pedro
dc.date.accessioned2021-12-09T20:01:18Z
dc.date.available2021-12-09T20:01:18Z
dc.date.issued2020-09-15
dc.description.abstractPurpose: There are limited published data regarding the use of supplemental intravitreal therapies in patients with diabetic macular edema (DME) following treatment with the 0.19 mg fluocinolone acetonide (FAc; ILUVIEN®) intravitreal implant. The aim of this report was to analyze five challenging eyes that required supplemental therapies after treatment with the FAc implant. Methods: This is a retrospective case series conducted at the Centro Hospitalar Universitário do Porto in Porto, Portugal, between 2015 and 2019. It aimed to assess the patient background, treatment history and patient outcomes in challenging clinical cases in which intravitreal injections (IVI) of ranibizumab had been given pro re nata following treatment with the FAc implant (with a minimum follow-up of 33 months). Parameters measured included best-corrected visual acuity in early treatment diabetic retinopathy scale, central macular thickness and intraocular pressure. Patients: Five eyes (three patients) diagnosed with persistent or recurrent DME and suitable for treatment with the FAc implant according to its licensed indication in Europe. Results: In the first 2 patients, one bilateral, DME was refractory to IVI of short-acting corticosteroids and anti-VEGF. Following FAc therapy, there was a favorable evolution and a clear regression of diabetic retinopathy (DR) severity. Supplemental treatments were adopted, but a reduced number of treatments were needed beyond three years in these cases. The third case had bilateral DME. One eye had been vitrectomized and FAc therapy led to resolution of DME within 6 months. In the contralateral eye, the control of DME was dependent on anti-VEGF supplemental treatments until a pars plana vitrectomy was performed. Conclusion: The multifactorial nature of DME means there is a need for an individualized treatment approach to the management of DME. It also explains why some patients need a combined or a more aggressive approach to therapy in order to achieve successful outcomes for the patient.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationPessoa B, Melo-Beirão J, Meireles A, Menéres P. Challenging Clinical Cases - A Walk Through Supplemental Therapy with Intravitreal Ranibizumab Therapy Following Treatment of Diabetic Macular Edema with the 0.19 mg Fluocinolone Acetonide Implant (ILUVIEN®). Int Med Case Rep J. 2020;13:437-448. doi:10.2147/IMCRJ.S262587pt_PT
dc.identifier.doi10.2147/IMCRJ.S262587pt_PT
dc.identifier.issn1179-142X
dc.identifier.urihttp://hdl.handle.net/10400.16/2653
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherDove Medical Presspt_PT
dc.relation.publisherversionhttps://www.dovepress.com/challenging-clinical-cases-ndash-a-walk-through-supplemental-therapy-w-peer-reviewed-fulltext-article-IMCRJpt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/pt_PT
dc.subjectanti-VEGFpt_PT
dc.subjectdiabetic macular edemapt_PT
dc.subjectfluocinolone acetonide implantpt_PT
dc.subjectranibizumabpt_PT
dc.subjectsupplemental therapypt_PT
dc.titleChallenging Clinical Cases – A Walk Through Supplemental Therapy with Intravitreal Ranibizumab Therapy Following Treatment of Diabetic Macular Edema with the 0.19 mg Fluocinolone Acetonide Implant (ILUVIEN®)pt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.conferencePlaceNew Zealandpt_PT
oaire.citation.endPage448pt_PT
oaire.citation.startPage437pt_PT
oaire.citation.titleInternational Medical Case Reports Journalpt_PT
oaire.citation.volumeVolume 13pt_PT
person.familyNamePessoa
person.familyNameBeirão
person.familyNameMeireles
person.familyNameMeneres
person.givenNameBernardete
person.givenNameJoão Nuno Melo
person.givenNameAngelina
person.givenNamePedro
person.identifier.ciencia-id0E1B-7EB2-B90F
person.identifier.ciencia-id0214-5233-EE9D
person.identifier.ciencia-idB112-8980-9E84
person.identifier.orcid0000-0002-5673-1561
person.identifier.orcid0000-0001-8642-7010
person.identifier.orcid0000-0001-9148-2786
person.identifier.orcid0000-0002-1989-3465
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationfa0e3b13-5da3-4f74-a184-22358fc19d38
relation.isAuthorOfPublication03b98348-ce82-4043-bb58-db089fcc21d6
relation.isAuthorOfPublication8832627a-5103-43bb-a479-6556c8b18d44
relation.isAuthorOfPublicationaddc269e-fbd0-41ae-b58c-46c3500ae580
relation.isAuthorOfPublication.latestForDiscoveryfa0e3b13-5da3-4f74-a184-22358fc19d38

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Pessoa-2020-Challenging-clinical-cases--a-walk-.pdf
Size:
5.09 MB
Format:
Adobe Portable Document Format
Download

Collections

SOFT - Artigos publicados em revistas indexadas na Pubmed/Medline